Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Canada
  4. Bourse de Toronto
  5. Therma Bright Inc.
  6. News
  7. Summary
    THRM   CA8834261080


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Therma Bright Successfully Up-lists to the OTCQB Venture Market Under Symbol TBRIF

09/14/2021 | 07:05am EDT

Toronto, Ontario--(Newsfile Corp. - September 14, 2021) -  Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, announced today its successful up-listing from the OTC Pink Sheets to the OTCQB® Venture Market (the "OTCQB"). Therma Bright will commence trading on the OTCQB with the market open on September 14, 2021, under the symbol "TBRIF".

"We're excited to be up-listed to the OTCQB, which is an important milestone for Therma Bright," shared Rob Fia, CEO of Therma Bright. "The OTCBQ affords us greater visibility within the U.S. investment community, which should enhance our liquidity and increase our access to institutional and retail investors. This additional capital markets exposure will be invaluable as we continue to buildout our AcuVid™, Venowave, Benepod™ and other product lines, along with their U.S. and global distribution sales channels."

The OTCQB, operated by OTC Markets Group Inc., is designed for developing and entrepreneurial companies in the United States and abroad. Companies must be current in their financial reporting and undergo an annual verification and management certification process, including meeting a minimum bid price and other financial conditions. With more compliance and quality standards, the OTCQB provides investors improved visibility to enhance trading decisions. The OTCQB is recognized by the United States Securities and Exchange Commission as an established public market providing public information for analysis and value of securities. B. Riley Securities acted as the Company's OTCQB sponsor. B. Riley Securities, Inc. is a full-service investment bank and subsidiary of B. Riley Financial, Inc., based in Los Angeles with offices across the United States, providing corporate finance, research, sales, and trading services.

As reported on September 1st, 2021, the Company successfully completed and submitted additional research and documentation requested by the FDA. Therma Bright has since received an acknowledgement letter from the FDA for the information submitted for the EUA submission. The information has been formally logged into the FDA system and is under review. Therma Bright will continue to work interactively with the FDA to provide additional information, if necessary, to complete the review.

Therma Bright is not making any express or implied claims that its test product has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.

About Therma Bright Inc.

Therma Bright, developer of the AcuVid™ COVID-19 Rapid Antigen Saliva Test, is a progressive medical diagnostic and device technology company focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. The Company's initial breakthrough proprietary technology delivers effective, non-invasive, and pain-free skincare. Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation of a variety of insect bites or stings. The Company received clearance for the above claims from the US FDA in 1997. Therma Bright Inc. trades on the TSXV (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: www.thermabright.com.

Therma Bright Inc.
Rob Fia, CEO

Follow us on Twitter


Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as development and commercialization of a rapid COVID-19 viral assay and related instrumentation. as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether or not such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities regulations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

This press release is not an offer of the securities for sale in the United States. The securities have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an exemption from registration. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/96452

© Newsfilecorp 2021
All news about THERMA BRIGHT INC.
10/04Therma Bright Inc Provides Update for its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test
09/14Therma Bright Successfully Up-lists to the OTCQB Venture Market Under Symbol TBRIF
09/01THERMA BRIGHT : Says Additional AcuVid COVID Saliva Test Documentation Submitted to FDA
09/01Therma Bright Provides Update on FDA-EUA Application Process
09/01Therma Bright Provides Update on FDA-EUA Application Process
08/12Therma Bright Enters into Securities for Services Agreement, Debt Settlement, and Issue..
08/05Therma Bright Inc. Finalizes Agreement with Afero, Inc. for Smart-Enabled Acuvid Saliva..
08/05Therma Bright Finalizes Agreement with Afero for Its Smart-Enabled AcuVid(TM) Saliva Te..
07/29THERMA BRIGHT : Applies for OTCQB Listing; Falls 1.3%
07/29Therma Bright Files Application to the OTCQB and DTC Clearing
More news
Sales 2020 0,00 M 0,00 M 0,00 M
Net income 2020 -0,63 M -0,51 M -0,51 M
Net cash 2020 0,97 M 0,78 M 0,78 M
P/E ratio 2020 -48,4x
Yield 2020 -
Capitalization 106 M 86,3 M 86,2 M
EV / Sales 2019 601x
EV / Sales 2020 7 753x
Nbr of Employees -
Free-Float 86,7%
Duration : Period :
Therma Bright Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Rob Fia Chairman, President & Chief Executive Officer
Victor Johan Hugo Chief Financial Officer
Joseph Heng Director
Andrew Timothy Peterson Director
Sungbum Spencer Huh Director
Sector and Competitors
1st jan.Capi. (M$)